Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

NCT00712582 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: Etoposide, carboplatin, ifosfamide
DRUG: Rituximab, Ifosfamide, Etoposide, Carboplatin
DRUG: Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]